Debt-to-Equity

With battery and solar costs plummeting, a new era of sustainable energy is dawning—driven by profit, not just policy. Here's the roadmap.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

After uniting nine acquired firms under one brand, NowVertical is shifting its focus to organic growth, leveraging integrated operations to exceed targets.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

VENU closes a $13M deal for its first indoor venue, bringing an innovative fractional ownership "FireSuite" concept to the Denver area.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

The real estate giant's mixed cash and stock distribution reveals a strategy to fuel growth amid a nearshoring frenzy, impacting investors and the market.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

With major acquisitions complete, Huntington's leadership will face investors to outline their vision for growth amid a complex economic landscape.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

UK service provider Kocho partners with Zadara, signaling a broader market shift away from VMware due to rising costs and the growing need for AI readiness.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

The Swedish industrial giant posted strong sales and improved margins for 2025, but a significant dip in new orders has investors watching the future closely.

The auto supplier's 2025 results show a profitable balance between legacy tech and EV innovation, fueled by post-acquisition operational discipline.